Ideas To Curb Surprise Medical Bills Percolate With Rare Bipartisan Push
The recent declaration by President Donald Trump that taming unexpected medical bills would be a top priority for his administration echoed through the halls of Congress.
The independent source for health policy research, polling, and news.
1,081 - 1,100 of 3,488 Results
The recent declaration by President Donald Trump that taming unexpected medical bills would be a top priority for his administration echoed through the halls of Congress.
The 2018 farm bill that legalized hemp created a loophole for an unregulated copycat of marijuana. A form of delta-9 THC — the psychoactive substance in pot — doesn’t face the same laws and regulations as marijuana because it comes from hemp. The drug is poised to upend the cannabis industry.
President Joe Biden and Republicans in Congress spent last month sparring over whether to shield Medicare and Social Security from budget cuts — leading some to wonder if Medicaid was on the table instead. Biden and Democrats say no, but some Republicans seem eager to trim federal spending on the health program for Americans with low incomes. And ready or not, artificial intelligence is coming to medical care. Benefits, as well as unintended consequences, are likely. Alice Miranda Ollstein of Politico, Rachel Cohrs of STAT News, and Lauren Weber of The Washington Post join KHN’s chief Washington correspondent, Julie Rovner, to discuss these issues and more.
She took a bad fall on the slopes and her surgeon used a metal plate to put the splintered bones of her leg back together. When that device failed less than four months later, she and her insurer had to pay full price for the replacement plate.
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it’s the arbitrators that jack up prices for those who can least afford them.
Abortion isn’t the only health issue voters will be asked to decide in state ballot questions next month. Proposals about medical debt, Medicaid expansion, and whether health care should be a right are on ballots in various states. Meanwhile, the latest lawsuit challenging the Affordable Care Act has expanded to cover all preventive care. Alice Miranda Ollstein of Politico, Jessie Hellmann of CQ Roll Call, and Victoria Knight of Axios join KHN’s Julie Rovner to discuss these topics and more.
Medicare Advantage, the private plan alternative to traditional Medicare, is embroiled in a growing controversy over whether insurers are being overpaid and what it would mean to reduce those payments. Meanwhile, even as maternal mortality in the U.S. continues to rise, providers of care to pregnant women say they’re leaving states with abortion bans that prevent them from treating pregnancy complications. Margot Sanger-Katz of The New York Times, Jessie Hellmann of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s chief Washington correspondent Julie Rovner to discuss these issues and more.
Private equity firms have shelled out almost $1 trillion to acquire nearly 8,000 health care businesses, in deals almost always hidden from federal regulators. The result: higher prices, lawsuits, and complaints about care.
KHN gives readers a chance to comment on a recent batch of stories.
People talk about the sacrifices they made when health care forced them into debt.
Pharmacy closures by two of the biggest home infusion companies point to grave shortages and dangers for patients who require IV nutrition to survive.
A new survey from the Centers for Disease Control and Prevention finds that teenagers, particularly girls, are reporting all-time high rates of violence and profound mental distress. Meanwhile, both sides in the abortion debate are anxiously waiting for a district court decision in Texas that could effectively revoke the FDA’s 22-year-old approval of the abortion pill mifepristone. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s chief Washington correspondent, Julie Rovner, to discuss these issues and more.
The legislation, which the House is expected to pass Friday, would allow the federal government, for the first time, to negotiate the price of some drugs that Medicare buys. It also would extend the enhanced subsidies for people who buy insurance on the Affordable Care Act marketplaces.
Missouri has more people waiting to have their Medicaid applications processed than it has approved since the expansion of the federal-state health insurance program. Although most states process Medicaid applications within a week, Missouri is taking, on average, more than two months. Patient advocates fear that means people will stay uninsured longer, leading them to postpone care or get stuck with high medical bills.
Public transit is already insufficient in rural areas, leaving residents with few options as they travel greater distances to access health care. But older residents who depend on volunteer drivers to get them to appointments face another challenge: The number of those volunteers is declining.
KHN gives readers a chance to comment on a recent batch of stories.
Congress is leaving for its annual summer break having accomplished far more than many expected, including, barring unforeseen snags, a bill to address the cost of prescription drugs for Medicare beneficiaries and extend the enhanced subsidies for insurance premiums under the Affordable Care Act. Meanwhile, the abortion issue continues to roil the nation as Indiana becomes the first state to ban the procedure in almost all cases since the Supreme Court overruled the constitutional right to abortion in June. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of “Medicare for All” maps out his strategy for negotiating with Republicans — and Big Pharma.
© 2026 KFF